Aurinia Pharmaceuticals stock surges 4% on plans to pursue a possible sale

Aurinia Pharmaceuticals (NASDAQ:) shares gained more than 4% after-hours as the company announced that its Board of Directors has begun exploring strategic alternatives. The board will carefully assess a broad range of possibilities for the company, which may include a potential sale, merger, or other strategic transactions.

There is no guarantee that this exploration will lead to any specific transaction or strategic outcome. The company has not established a timeline for concluding this process, and it does not plan to disclose additional updates unless it deems it necessary or appropriate to do so.